Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Keyword(s):
Phase 3
◽
1999 ◽
Vol 35
◽
pp. S314
◽
Keyword(s):